Page last updated: 2024-10-29

ketamine and Lower Urinary Tract Symptom

ketamine has been researched along with Lower Urinary Tract Symptom in 36 studies

Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.

Research Excerpts

ExcerptRelevanceReference
"Ketamine-associated cystitis is a new urinary system inflammatory damage."8.89[Diagnosis and treatment of ketamine-associated cystitis: a report of 3 cases and literature review]. ( Ding, J; Huang, K; Huang, L; Li, D; Li, Y; Luo, K; Tang, Z; Wang, G; Zhou, J, 2013)
"We aimed to explore the correlation between ketamine abuse and lower urinary tract symptoms (LUTS) and epidemiology of ketamine cystitis."7.91A survey for ketamine abuse and its relation to the lower urinary tract symptoms in Taiwan. ( Cha, TL; Li, CC; Meng, E; Sun, GH; Wu, ST; Yu, DS, 2019)
"Young adults with longstanding ketamine abuse present with lower urinary tract symptoms (LUTSs), which may be accompanied by urinary tract infection (UTI)."7.91Epidemiologic characteristics and risk factors in patients with ketamine-associated lower urinary tract symptoms accompanied by urinary tract infection: A cross-sectional study. ( Gao, Y; Hong, F; Li, T; Liu, W; Wei, Y; Wu, J; Wu, W; Yang, J; Ye, L; Zhu, Q, 2019)
"Long-term ketamine abuse can affect the urinary system, resulting in lower urinary tract symptoms (LUTS), but the pathogenesis of this is still unknown."7.83BDNF-ERK1/2 signaling pathway in ketamine-associated lower urinary tract symptoms. ( Cao, Y; Gao, Z; Liu, T; Liu, Z; Peng, B; Wang, X; Xu, C, 2016)
"Ketamine cystitis is a complex problem whose exact pathological mechanism and natural history remain unknown."7.80Ketamine cystitis: practical considerations in management. ( Chetwood, A; Coker, C; Misra, S; Thomas, P, 2014)
"The Chinese version of the pelvic pain and urgency/frequency questionnaire is reliable and valid for assessment in patients with street-ketamine-associated lower urinary tract symptoms."7.78The Chinese version of the pelvic pain and urgency/frequency symptom scale: a useful assessment tool for street-ketamine abusers with lower urinary tract symptoms. ( Ma, WK; Ng, CM; To, KC; Yiu, MK, 2012)
"We examined the association of lower urinary tract symptoms and levels of Nectin-4, a member of the cell adhesion molecules that is essential for maintaining the urothelium barrier in chronic ketamine abusers."5.62Increased Nectin-4 levels in chronic ketamine abusers and the relationship with lower urinary tract symptoms. ( Chang, HM; Chen, PY; Fang, CP; Hsu, YC; Huang, MC; Kuo, HW; Liu, TH; Liu, YL; Wu, CT, 2021)
"Ketamine is a recreational drug widely abused in East Asia and also in certain subpopulations of the United States."5.46Ketamine Abuse Syndrome: Hepatobiliary and Urinary Pathology Among Adolescents in Flushing, NY. ( Gordon, L; Kivovich, V; Wang, JW, 2017)
"Ketamine-associated cystitis is a new urinary system inflammatory damage."4.89[Diagnosis and treatment of ketamine-associated cystitis: a report of 3 cases and literature review]. ( Ding, J; Huang, K; Huang, L; Li, D; Li, Y; Luo, K; Tang, Z; Wang, G; Zhou, J, 2013)
"We aimed to explore the correlation between ketamine abuse and lower urinary tract symptoms (LUTS) and epidemiology of ketamine cystitis."3.91A survey for ketamine abuse and its relation to the lower urinary tract symptoms in Taiwan. ( Cha, TL; Li, CC; Meng, E; Sun, GH; Wu, ST; Yu, DS, 2019)
"Young adults with longstanding ketamine abuse present with lower urinary tract symptoms (LUTSs), which may be accompanied by urinary tract infection (UTI)."3.91Epidemiologic characteristics and risk factors in patients with ketamine-associated lower urinary tract symptoms accompanied by urinary tract infection: A cross-sectional study. ( Gao, Y; Hong, F; Li, T; Liu, W; Wei, Y; Wu, J; Wu, W; Yang, J; Ye, L; Zhu, Q, 2019)
"This study investigated the risk factors of ketamine associated-lower urinary tract symptoms (LUTS), such as duration of use, dosage of ketamine, co-occurring substance use of other psychoactive drugs, comorbidities, and depression."3.88Risk Factors of Lower Urinary Tract Syndrome among Ketamine Users. ( Chen, IC; Chen, WC; Hu, TC; Lee, MH; Lin, HY, 2018)
"To evaluate the prevalence of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) in the illicit male ketamine abusers (KA)."3.88Sexual and bladder dysfunction in male ketamine abusers: A large-scale questionnaire study. ( Chang, SJ; Chen, WS; Chen, YC; Hsu, WT; Jang, MY; Lee, KH; Yang, SS, 2018)
"Ketamine cystitis is a complex problem whose exact pathological mechanism and natural history remain unknown."3.80Ketamine cystitis: practical considerations in management. ( Chetwood, A; Coker, C; Misra, S; Thomas, P, 2014)
" What's known on the subject? and What does the study add? Case series have described lower urinary tract symptoms associated with ketamine use including severe pain, frequency, haematuria and dysuria."3.78The prevalence and natural history of urinary symptoms among recreational ketamine users. ( Cottrell, AM; Gillatt, DA; Mitcheson, L; Winstock, AR, 2012)
"The Chinese version of the pelvic pain and urgency/frequency questionnaire is reliable and valid for assessment in patients with street-ketamine-associated lower urinary tract symptoms."3.78The Chinese version of the pelvic pain and urgency/frequency symptom scale: a useful assessment tool for street-ketamine abusers with lower urinary tract symptoms. ( Ma, WK; Ng, CM; To, KC; Yiu, MK, 2012)
"We describe the severe lower urinary tract symptoms experienced in 6 patients with chronic recreational ketamine use."3.78Ketamine-associated urinary tract dysfunction: an underrecognized clinical entity. ( Cai, Z; Chen, Z; Guan, Z; Gui, Y; Lai, Y; Li, X; Ni, L; Wu, S; Yang, S; Ye, J, 2012)
"We analyzed the imaging findings in 45 patients with KAUD, all having a history of ketamine abuse and presenting with severe lower urinary tract symptoms."3.78[Imaging features of urinary dysfunction associated with ketamine abuse]. ( Gao, L; Gu, D; Huang, J; Huang, Z; Wang, Y; Wu, P; Zhao, J; Zheng, H; Zheng, S, 2012)
"Group K had significantly decreased postoperative pain scores at 1, 2, 6, and 12 h."2.80CLINICAL RESEARCH REGARDING PREEMPTIVE ANALGESIC EFFECT OF PREOPERATIVE KETAMINE AFTER TRANSURETHRAL RESECTION OF PROSTATE. ( Fu, Y; Ma, H; Wang, J; Wang, N, 2015)
"Ketamine is a relatively new recreational drug used by youngsters in recent decades."2.49Genitourinary toxicity of ketamine. ( Guo, Q; Liang, BL; Wei, YB; Yang, JR; Yin, Z; Zhou, KQ, 2013)
"It is reported to cause lower urinary tract symptoms (LUTS), and published accounts of its deleterious effects are increasing."2.47Ketamine-induced vesicopathy: a literature review. ( Middela, S; Pearce, I, 2011)
"LUTS (Interstitial Cystitis Symptom Index [ICSI] + Interstitial Cystitis Problem Index [ICPI] ≥12) was found to be a significant risk factor for FSD in KAs."1.91Relationship between sexual and bladder dysfunction in women consuming ketamine. ( Chang, SJ; Jong, BE; Li, CH; Yang, SS, 2023)
"We examined the association of lower urinary tract symptoms and levels of Nectin-4, a member of the cell adhesion molecules that is essential for maintaining the urothelium barrier in chronic ketamine abusers."1.62Increased Nectin-4 levels in chronic ketamine abusers and the relationship with lower urinary tract symptoms. ( Chang, HM; Chen, PY; Fang, CP; Hsu, YC; Huang, MC; Kuo, HW; Liu, TH; Liu, YL; Wu, CT, 2021)
"Ketamine is known to cause urinary tract dysfunction."1.51Substance abuse effects on urinary tract: methamphetamine and ketamine. ( Hong, YL; Lai, PT; Ng, CF; Tam, YH; Yee, CH, 2019)
"Ketamine is a recreational drug widely abused in East Asia and also in certain subpopulations of the United States."1.46Ketamine Abuse Syndrome: Hepatobiliary and Urinary Pathology Among Adolescents in Flushing, NY. ( Gordon, L; Kivovich, V; Wang, JW, 2017)
"Lower urinary tract symptoms are prevalent in the general adolescent population."1.43Population-based survey of the prevalence of lower urinary tract symptoms in adolescents with and without psychotropic substance abuse. ( Hong, YL; Lai, PT; Lee, WM; Ng, CF; Pang, KK; Tam, YH; Wong, YS, 2016)
"Ketamine is a short-acting anaesthetic agent that has gained popularity as a 'club drug' due to its hallucinogenic effects."1.42The clinical presentation and diagnosis of ketamine-associated urinary tract dysfunction in Singapore. ( Aydin, H; Kuo, T; Ng, LG; Sundaram, P; Yek, J, 2015)
"Ketamine bladder is a new clinical entity that may lead to irreversible damage to the urinary system."1.38Illicit ketamine and its bladder consequences: is it irreversible? ( Gupta, S; Jalil, R, 2012)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's32 (88.89)24.3611
2020's4 (11.11)2.80

Authors

AuthorsStudies
Lee, TS1
Liu, YH1
Huang, YJ1
Tang, WK1
Wang, Y9
Hu, S1
Lin, CP1
Li, CR1
Hung, CC1
Jong, BE1
Chang, SJ2
Li, CH1
Yang, SS2
Yee, CH1
Ng, CF2
Hong, YL2
Lai, PT2
Tam, YH2
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J7
Huang, L3
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S2
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X5
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X5
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z4
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH3
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S2
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C2
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J2
Lu, Y1
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W2
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D3
Zheng, S3
Ma, L1
Wang, L3
Hu, T1
Wang, F1
Han, Z1
Yin, Z2
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L2
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y5
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z3
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T3
Chen, D5
Luo, K2
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q3
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W2
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J4
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y3
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z3
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J3
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J2
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P2
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y2
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
McIntyre, RS1
Rosenblat, JD1
Nemeroff, CB1
Sanacora, G1
Murrough, JW1
Berk, M1
Brietzke, E1
Dodd, S1
Gorwood, P1
Ho, R1
Iosifescu, DV1
Lopez Jaramillo, C1
Kasper, S1
Kratiuk, K1
Lee, JG1
Lee, Y1
Lui, LMW1
Mansur, RB1
Papakostas, GI1
Subramaniapillai, M1
Thase, M1
Vieta, E1
Young, AH1
Zarate, CA1
Stahl, S1
Chang, HM1
Chen, PY1
Fang, CP1
Liu, TH1
Wu, CT1
Hsu, YC1
Kuo, HW1
Liu, YL1
Huang, MC1
Chen, IC1
Lee, MH1
Chen, WC1
Hu, TC1
Lin, HY1
Jang, MY1
Lee, KH1
Hsu, WT1
Chen, YC1
Chen, WS1
Li, CC1
Wu, ST1
Cha, TL1
Sun, GH1
Yu, DS1
Meng, E1
Li, T1
Zhu, Q1
Ye, L1
Hong, F1
Wei, YB2
Yang, JR2
Liang, BL1
Zhou, KQ1
Schaeffer, EM2
Tang, Z1
Wang, G1
Ding, J1
Huang, K1
Zhou, J1
Wein, AJ1
Reinhardt, S2
Fode, M2
Misra, S1
Chetwood, A1
Coker, C1
Thomas, P1
Peng, TR1
Lee, MC1
Wu, TW1
Lan, CC1
Cheung, RY1
Chan, SS1
Liu, DW1
Choy, KW1
Wang, JW1
Kivovich, V1
Gordon, L1
Yek, J1
Sundaram, P1
Aydin, H1
Kuo, T1
Ng, LG1
Wang, N1
Fu, Y1
Ma, H1
Peng, B1
Gao, Z1
Cao, Y1
Wong, YS1
Pang, KK1
Lee, WM1
Myers, FA1
Bluth, MH1
Cheung, WW1
Middela, S1
Pearce, I1
Chen, WH1
Guan, ZC1
Winstock, AR1
Mitcheson, L1
Gillatt, DA1
Cottrell, AM1
Ng, CM1
Ma, WK1
To, KC1
Yiu, MK1
Lai, Y1
Gui, Y1
Guan, Z1
Cai, Z1
Song, W1
Zhao, J1
Gao, L1
Zheng, H1
Gu, D1
Srirangam, S1
Mercer, J1
Jalil, R1
Gupta, S1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Intravenous Low-dose Esketamine on Maternal Depression at 2 Years After Childbirth in Women With Prenatal Depression: 2-year Follow-up of a Randomized Controlled Trial[NCT05698394]Phase 4364 participants (Actual)Interventional2020-06-19Active, not recruiting
Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State[NCT06133309]15 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis[NCT04821882]29 participants (Actual)Interventional2019-05-01Completed
Prospective Longitudinal Study on the Treatment Outcomes of Various Treatment Modalities Under a Standardized Treatment Protocol in Patients Suffered Substance Abuse Related Voiding Dysfunction[NCT03913819]1,000 participants (Anticipated)Observational2011-12-10Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

9 reviews available for ketamine and Lower Urinary Tract Symptom

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    The American journal of psychiatry, 2021, 05-01, Volume: 178, Issue:5

    Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre

2021
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    The American journal of psychiatry, 2021, 05-01, Volume: 178, Issue:5

    Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre

2021
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    The American journal of psychiatry, 2021, 05-01, Volume: 178, Issue:5

    Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre

2021
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    The American journal of psychiatry, 2021, 05-01, Volume: 178, Issue:5

    Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre

2021
Genitourinary toxicity of ketamine.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2013, Volume: 19, Issue:4

    Topics: Anesthetics, Dissociative; Animals; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Symptoms; S

2013
[Diagnosis and treatment of ketamine-associated cystitis: a report of 3 cases and literature review].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2013, Volume: 38, Issue:9

    Topics: Biopsy; Cystitis; Cystoscopy; Humans; Ketamine; Lower Urinary Tract Symptoms; Recurrence; Retrospect

2013
[Bladder pain and urinary tract symptoms as a consequence of ketamine abuse].
    Ugeskrift for laeger, 2014, Feb-03, Volume: 176, Issue:3

    Topics: Analgesics; Hallucinogens; Hematuria; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Symptoms;

2014
Suspected ketamine-associated lower urinary tract symptoms.
    Urology journal, 2014, May-07, Volume: 11, Issue:2

    Topics: Humans; Hydronephrosis; Ketamine; Lower Urinary Tract Symptoms; Male; Middle Aged; Urinary Bladder D

2014
Ketamine: A Cause of Urinary Tract Dysfunction.
    Clinics in laboratory medicine, 2016, Volume: 36, Issue:4

    Topics: Analgesics; Cystitis; Diagnosis, Differential; Female; Humans; Ketamine; Lower Urinary Tract Symptom

2016
Ketamine-induced vesicopathy: a literature review.
    International journal of clinical practice, 2011, Volume: 65, Issue:1

    Topics: Excitatory Amino Acid Antagonists; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Symptoms; Su

2011
Ketamine-induced vesicopathy: a literature review.
    International journal of clinical practice, 2011, Volume: 65, Issue:1

    Topics: Excitatory Amino Acid Antagonists; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Symptoms; Su

2011
Ketamine-induced vesicopathy: a literature review.
    International journal of clinical practice, 2011, Volume: 65, Issue:1

    Topics: Excitatory Amino Acid Antagonists; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Symptoms; Su

2011
Ketamine-induced vesicopathy: a literature review.
    International journal of clinical practice, 2011, Volume: 65, Issue:1

    Topics: Excitatory Amino Acid Antagonists; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Symptoms; Su

2011
[Ketamine-associated urinary tract damage].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2011, Aug-18, Volume: 43, Issue:4

    Topics: Anesthetics, Dissociative; Humans; Ketamine; Lower Urinary Tract Symptoms

2011

Trials

2 trials available for ketamine and Lower Urinary Tract Symptom

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
CLINICAL RESEARCH REGARDING PREEMPTIVE ANALGESIC EFFECT OF PREOPERATIVE KETAMINE AFTER TRANSURETHRAL RESECTION OF PROSTATE.
    Middle East journal of anaesthesiology, 2015, Volume: 23, Issue:3

    Topics: Administration, Intravenous; Aged; Analgesics; Double-Blind Method; Humans; Ketamine; Laryngeal Mask

2015

Other Studies

26 other studies available for ketamine and Lower Urinary Tract Symptom

ArticleYear
Clinical and behavior characteristics of individuals who used ketamine.
    Scientific reports, 2022, 01-17, Volume: 12, Issue:1

    Topics: Adolescent; Adult; Cross-Sectional Studies; Female; Humans; Impulsive Behavior; Ketamine; Lower Urin

2022
Relationship between sexual and bladder dysfunction in women consuming ketamine.
    The journal of sexual medicine, 2023, 03-31, Volume: 20, Issue:4

    Topics: Adult; Cross-Sectional Studies; Cystitis, Interstitial; Female; Humans; Ketamine; Lower Urinary Trac

2023
Substance abuse effects on urinary tract: methamphetamine and ketamine.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2019, Volume: 25, Issue:6

    Topics: Adult; Cohort Studies; Female; Hong Kong; Humans; Ketamine; Lower Urinary Tract Symptoms; Male; Meth

2019
Increased Nectin-4 levels in chronic ketamine abusers and the relationship with lower urinary tract symptoms.
    Environmental toxicology and pharmacology, 2021, Volume: 87

    Topics: Adult; Cell Adhesion Molecules; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Lower U

2021
Risk Factors of Lower Urinary Tract Syndrome among Ketamine Users.
    Lower urinary tract symptoms, 2018, Volume: 10, Issue:3

    Topics: Adult; Analgesics; Comorbidity; Cross-Sectional Studies; Cystitis, Interstitial; Depression; Female;

2018
Sexual and bladder dysfunction in male ketamine abusers: A large-scale questionnaire study.
    PloS one, 2018, Volume: 13, Issue:11

    Topics: Adult; Erectile Dysfunction; Humans; Ketamine; Lower Urinary Tract Symptoms; Male; Risk Factors; Sub

2018
A survey for ketamine abuse and its relation to the lower urinary tract symptoms in Taiwan.
    Scientific reports, 2019, 05-10, Volume: 9, Issue:1

    Topics: Administration, Intravesical; Adult; Cystitis, Interstitial; Female; Humans; Ketamine; Lower Urinary

2019
Epidemiologic characteristics and risk factors in patients with ketamine-associated lower urinary tract symptoms accompanied by urinary tract infection: A cross-sectional study.
    Medicine, 2019, Volume: 98, Issue:23

    Topics: Adult; Cross-Sectional Studies; Female; Humans; Ketamine; Lower Urinary Tract Symptoms; Male; Risk F

2019
Dependence and urinary symptoms among recreational ketamine users.
    BJU international, 2013, Volume: 111, Issue:3

    Topics: Anesthetics, Dissociative; Female; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Symptoms; Ma

2013
Re: the prevalence and natural history of urinary symptoms among recreational ketamine users.
    The Journal of urology, 2013, Volume: 190, Issue:2

    Topics: Anesthetics, Dissociative; Female; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Symptoms; Ma

2013
Re: The prevalence and natural history of urinary symptoms among recreational ketamine users.
    The Journal of urology, 2013, Volume: 190, Issue:5

    Topics: Anesthetics, Dissociative; Female; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Symptoms; Ma

2013
[Ketamine-induced urinary symptoms].
    Ugeskrift for laeger, 2014, 02-03, Volume: 176, Issue:3

    Topics: Adult; Analgesics; Hallucinogens; Hematuria; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Sy

2014
Ketamine cystitis: practical considerations in management.
    Scandinavian journal of urology, 2014, Volume: 48, Issue:5

    Topics: Adolescent; Adult; Cystitis; Female; Humans; Ketamine; Lower Urinary Tract Symptoms; Male; Middle Ag

2014
A pilot study of urine cytokines in ketamine-associated lower urinary tract symptoms.
    International urogynecology journal, 2014, Volume: 25, Issue:12

    Topics: Adolescent; Adult; Analgesics; Biomarkers; Case-Control Studies; Chemokines; Cytokines; Disease Prog

2014
Ketamine Abuse Syndrome: Hepatobiliary and Urinary Pathology Among Adolescents in Flushing, NY.
    Pediatric emergency care, 2017, Volume: 33, Issue:8

    Topics: Abdominal Pain; Adolescent; Adult; Anesthetics, Dissociative; Asian; Delayed Diagnosis; Emigrants an

2017
The clinical presentation and diagnosis of ketamine-associated urinary tract dysfunction in Singapore.
    Singapore medical journal, 2015, Volume: 56, Issue:12

    Topics: Adult; Cystitis; Cystoscopy; Female; Fluoroscopy; Humans; Ketamine; Lower Urinary Tract Symptoms; Ma

2015
Re: Ketamine Cystitis: Practical Considerations in Management.
    The Journal of urology, 2016, Volume: 195, Issue:2

    Topics: Cystitis; Female; Humans; Ketamine; Lower Urinary Tract Symptoms; Male; Substance-Related Disorders

2016
BDNF-ERK1/2 signaling pathway in ketamine-associated lower urinary tract symptoms.
    International urology and nephrology, 2016, Volume: 48, Issue:9

    Topics: Analgesics; Animals; Brain-Derived Neurotrophic Factor; Female; Ketamine; Lower Urinary Tract Sympto

2016
Population-based survey of the prevalence of lower urinary tract symptoms in adolescents with and without psychotropic substance abuse.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2016, Volume: 22, Issue:5

    Topics: Adolescent; Age Factors; Child; Cross-Sectional Studies; Female; Hong Kong; Humans; Ketamine; Lower

2016
The prevalence and natural history of urinary symptoms among recreational ketamine users.
    BJU international, 2012, Volume: 110, Issue:11

    Topics: Abdominal Pain; Adult; Anesthetics, Dissociative; Cohort Studies; Cystitis; Female; Humans; Illicit

2012
The Chinese version of the pelvic pain and urgency/frequency symptom scale: a useful assessment tool for street-ketamine abusers with lower urinary tract symptoms.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2012, Volume: 18, Issue:2

    Topics: Adolescent; Adult; Cross-Sectional Studies; Female; Humans; Ketamine; Language; Lower Urinary Tract

2012
Ketamine-associated urinary tract dysfunction: an underrecognized clinical entity.
    Urologia internationalis, 2012, Volume: 89, Issue:1

    Topics: Administration, Intravesical; Adult; Biopsy; China; Cystoscopy; Female; Humans; Hyaluronic Acid; Ill

2012
Gourd-shaped bladder associated with ketamine abuse.
    Urologia internationalis, 2012, Volume: 89, Issue:1

    Topics: Adult; Cystitis; Dysuria; Hematuria; Humans; Illicit Drugs; Ketamine; Lower Urinary Tract Symptoms;

2012
[Imaging features of urinary dysfunction associated with ketamine abuse].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2012, Volume: 32, Issue:8

    Topics: Adolescent; Adult; Female; Humans; Ketamine; Lower Urinary Tract Symptoms; Magnetic Resonance Imagin

2012
Ketamine bladder syndrome: an important differential diagnosis when assessing a patient with persistent lower urinary tract symptoms.
    BMJ case reports, 2012, Sep-30, Volume: 2012

    Topics: Adult; Diagnosis, Differential; Humans; Ketamine; Lower Urinary Tract Symptoms; Male; Nocturia; Subs

2012
Illicit ketamine and its bladder consequences: is it irreversible?
    BMJ case reports, 2012, Oct-30, Volume: 2012

    Topics: Adult; Anesthetics, Dissociative; Cystitis; Female; Humans; Illicit Drugs; Ketamine; Lower Urinary T

2012